Quantcast

AxoGen, Inc. Announces Health Canada Approval for AxoGuard® Nerve Connector and AxoGuard® Nerve Protector

June 4, 2013

New Products for Peripheral Nerve Repair and Protection to be available to Canadian Surgeons and Patients

Alachua, FL (PRWEB) June 04, 2013

AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, today announced Health Canada Approval for AxoGuard® Nerve Connector and AxoGuard® Nerve Protector. The AxoGuard® Products, along with AxoGen´s proprietary Avance® Nerve Graft, were featured at the Company´s booth at the 67th Annual Meeting of the Canadian Society of Plastic Surgeons, which was held May 28 to June 1, 2013, in Calgary, Alberta. AxoGen will utilize its existing distribution partner in Canada to sell the products.

AxoGen CEO Karen Zaderej commented, “With the Health Canada approval for our AxoGuard® Products, we now have the opportunity to sell our full nerve repair portfolio in Canada. We featured the products at the Canadian Society of Plastic Surgeons´ annual meeting, highlighting the unique benefits that Avance® Nerve Graft and the AxoGuard® Products offer to plastic surgeons specializing in microsurgery. This is a key demographic for our products, and we are pleased with the positive reception we received from the surgeons in attendance. ”

AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are derived from porcine submucosa extracellular matrix. AxoGuard® Nerve Connector is a coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. Both products are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen.

The AxoGuard® Products are complementary to AxoGen´s Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging nerve discontinuities (gaps created when nerves are severed), which is available in the US, Canada, Austria, Italy and Switzerland.

For more information on AxoGen and its technology, please visit http://www.axogeninc.com.

About AxoGen, Inc.

AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company´s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen´s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves; and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.

AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen´s principal executive office and operations are located in Alachua, FL.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management´s current expectations or predictions of future conditions, events or results based on various assumptions and management´s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential, financial performance, sales growth, product adoption, market awareness of our products and data validation. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen´s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen´s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10798229.htm


Source: prweb



comments powered by Disqus